Check-Cap Ltd (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, an ingestible capsule for the prevention of colorectal cancer, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported research and development expenses at USD2.3m for the three months ended 31 March 2019, compared to USD1.6m for the same period in 2018.
The firm posted an operating loss of USD3.2m for the three months ended 31 March 2019, as against an operating loss of USD2.1m for the same period in 2018.
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
Hemogenyx reports positive safety and early efficacy data from third patient in CAR-T trial
Sanofi reports positive phase 2a results for brivekimig in hidradenitis suppurativa
GSK commits USD30bn to US R&D and manufacturing expansion
Neurocrine Biosciences announces presentation of Osavampator Phase 2 data at Psych Congress 2025
Ascletis presents ASC30 study results at EASD Annual Meeting
Three WuXi Biologics manufacturing facilities receive GMP certification from Turkish regulator
VarmX secures strategic collaboration and option agreement with CSL for novel coagulation therapy
Avidity Biosciences closes USD690m public offering of common stock
Akeso's ligufalimab (CD47 mAb) granted FDA Orphan Drug Designation for AML
Forte Biosciences highlights positive FB102 data in celiac disease at Tampere Symposium
SureSpace Launches in Dubai to Tackle Doomscrolling and Redefine Social Networking
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Biophytis secures Brazilian funding and partnerships for obesity Phase 2 trial